產(chǎn)品名稱 | SW480 [SW-480] |
---|---|
商品貨號 | B165797 |
Organism | Homo sapiens, human |
Tissue | colon |
Product Format | frozen |
Morphology | epithelial |
Culture Properties | adherent |
Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease | Dukes' type B, colorectal adenocarcinoma |
Age | 50 years |
Gender | male |
Ethnicity | Caucasian |
Applications | This cell line is a suitable transfection host. This line has a mutation in codon 12 of the ras proto-oncogene, and can be used as a positive control for PCR assays of mutation in this codon. |
Storage Conditions | liquid nitrogen vapor phase |
Karyotype | The stemline chromosome number is hypotriploid and 11-12 marker chromosomes were common. Both double minutes and dicentrics were observed in 8% of each metaphase examined. |
Images | |
Derivation | SW480 was established from a primary adenocarcinoma of the colon. |
Clinical Data | 50 years
Caucasian
male |
Receptor Expression | epidermal growth factor (EGF) |
Oncogene | myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src - |
Genes Expressed | carcinoembryonic antigen (CEA) 0.7 ng/10 6 cells/10 days; keratin; transforming growth factor beta,myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src -,HLA A2, B8, B17; blood type A; Rh+,The cells are positive for keratin by immunoperoxidase staining.,The line is positive for expression of c-myc, K-ras, H-ras, N-ras, myb, sis and fos oncogenes. |
Cellular Products | carcinoembryonic antigen (CEA) 0.7 ng/10 exp6 cells/10 days; keratin; transforming growth factor beta |
Tumorigenic | Yes. Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells. |
Effects | Yes, in nude mice |
Virus Susceptibility | Human immunodeficiency virus 1
,
Human immunodeficiency virus 1 |
Comments | A cell line established from a lymph node metastasis taken from the same patient one year later is available (see ATCC CCL-227). The line is negative for CSAp (CSAp-) and colon antigen 3. The cells are positive for keratin by immunoperoxidase staining. There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution and a C -> T mutation in codon 309 resulting in a Pro -> Ser substitution. The cells express elevated levels of p53 protein. The line is positive for expression of c-myc, K-ras, H-ras, N-ras, myb, sis and fos oncogenes. N-myc oncogene expression was not detected. Matrilysin, a metalloproteinase associated with tumor invasiveness, is not expressed. The cells have been reported to produce GM-CSF. |
Complete Growth Medium | The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. (Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation) |
Subculturing | Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:8 is recommended
Medium Renewal: 1 to 2 times per week
|
Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
Culture Conditions | Atmosphere: air, 100%
Temperature: 37°C |
STR Profile | Amelogenin: X CSF1PO: 13,14 D13S317: 12 D16S539: 13 D5S818: 13 D7S820: 8 THO1: 8 TPOX: 11 vWA: 16 |
Isoenzymes | ES-D, 1 G6PD, B PEP-D, 1 PGD, A PGM1, 2 PGM3, 1 |
Name of Depositor | A Leibovitz |
Deposited As | Homo sapiens |
References | Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034 Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927 Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832 Schroy PC, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-209, 1995. PubMed: 8625092 Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874 Weiss J, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54: 693-699, 1993. PubMed: 8514460 Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845 Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498 Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501 Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289 Lahm H, et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res. 54: 3700-3702, 1994. PubMed: 8033086 Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228 Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479 Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066 Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224 Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282 |
梅經(jīng)理 | 17280875617 | 1438578920 |
胡經(jīng)理 | 13345964880 | 2438244627 |
周經(jīng)理 | 17757487661 | 1296385441 |
于經(jīng)理 | 18067160830 | 2088210172 |
沈經(jīng)理 | 19548299266 | 2662369050 |
李經(jīng)理 | 13626845108 | 972239479 |